These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33098760)

  • 1. How current assay approval policies are leading to unintended imprecision medicine.
    Salgado R; Bellizzi AM; Rimm D; Bartlett JMS; Nielsen T; Holger M; Laenkholm AV; Quinn C; Cserni G; Cunha IW; Alvarado-Cabrero I; Cree I
    Lancet Oncol; 2020 Nov; 21(11):1399-1401. PubMed ID: 33098760
    [No Abstract]   [Full Text] [Related]  

  • 2. A Precision Medicine Approach to Clinical Trials.
    Rubin R
    JAMA; 2016 Nov; 316(19):1953-1955. PubMed ID: 27760248
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward a Personalized Use of Paclitaxel.
    Russo GL
    Recent Pat Anticancer Drug Discov; 2019; 14(4):296-297. PubMed ID: 31920185
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges ahead for companion diagnostics.
    Schmidt C
    J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 8. That's how you make drugs!
    Kapitein P
    Chin Clin Oncol; 2016 Dec; 5(6):82. PubMed ID: 27334463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative Clinical Trial Designs Lead to New Drug Approvals.
    Miller DJ
    ONS Connect; 2016 Mar; 31(3):22. PubMed ID: 27044204
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
    Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
    Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment.
    Lawler SE; Chiocca EA
    J Clin Oncol; 2015 Sep; 33(25):2812-4. PubMed ID: 26215964
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in theranostic biomarkers for tumor immunotherapy.
    Bellesoeur A; Torossian N; Amigorena S; Romano E
    Curr Opin Chem Biol; 2020 Jun; 56():79-90. PubMed ID: 32217357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating cancer research into targeted therapeutics.
    de Bono JS; Ashworth A
    Nature; 2010 Sep; 467(7315):543-9. PubMed ID: 20882008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
    Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
    Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is genome-guided cancer treatment hyped?
    Kaiser J
    Science; 2018 Apr; 360(6387):365. PubMed ID: 29700244
    [No Abstract]   [Full Text] [Related]  

  • 18. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

  • 20. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
    Kato S; Subbiah V; Kurzrock R
    J Natl Compr Canc Netw; 2017 Jul; 15(7):863-866. PubMed ID: 28687573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.